Trump Announces Pricing Deals With Nine Drugmakers

In a move to address the high cost of prescription drugs, President Trump has announced pricing deals with nine major pharmaceutical companies. These deals will allow Medicaid and consumers to purchase certain drugs at discounted prices. The companies involved in the agreements include Merck, Eli Lilly, Amgen, Pfizer, Novartis, Sanofi, Bristol-Myers Squibb, AstraZeneca, and Gilead Sciences. The president stated that these deals are part of his administration's ongoing efforts to lower drug prices and make healthcare more affordable for Americans. Additionally, Trump revealed that he plans to initiate similar negotiations with health insurance providers in the near future. This suggests a broader strategy to tackle the issue of rising healthcare costs from multiple angles, involving both drug manufacturers and insurance companies. The announcement comes amid growing concerns over the affordability of prescription drugs, which have been a significant burden for many individuals and families. The administration's efforts to address this problem are seen as a step towards making healthcare more accessible and improving the overall well-being of the American public.